Inici › Leucèmia › Massachusetts › Boston
Assaigs clínics de Leucèmia a Boston, MA
25 estudis de Leucèmia busquen participants en centres de Boston i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
ReclutantFase 2
- Dana-Farber Cancer Institute, Boston
Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
Reclutant
- Dana-Farber Cancer Institute, Boston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
ReclutantFase 3
- Research Site, Boston
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
ReclutantFase 2
- Massachusetts General Hospital, Boston
CIML NK Cells With Venetoclax for AML
ReclutantFase 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
ReclutantFase 1
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
ReclutantFase 1
- Beth Israel Deaconess Medical Center, Boston
ALL Backbone in AYAs
ReclutantFase 2
- Dana Farber Cancer Institute, Boston
Addressing Cancer Care Equity With Social Determinants of Health Screening and Early Intervention
Reclutant
- Mass General Brigham Cancer Institute, Boston
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
ReclutantVoluntaris sans benvinguts
- Dana-Farber Cancer Institute, Boston
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
ReclutantFase 1
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
ReclutantFase 1
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
ReclutantFase 1/2
- Dren Investigational Site, Boston
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
ReclutantFase 1
- Dana-Farber Cancer Institute, Boston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
ReclutantEstudi observacional
- Dana-Farber Cancer Institute, Boston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
ReclutantFase 2/3
- Dana-Farber Cancer Institute, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Reclutant
- Massachusetts General Hospital Cancer Center, Boston
Shwachman Diamond Syndrome Registry and Study
ReclutantEstudi observacional
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Revumenib in Combination With 7+3 + Midostaurin in AML
ReclutantFase 1
- Dana-Farber Cancer Institute, Boston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
ReclutantFase 1
- Massachusetts General Hospital, Boston
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
ReclutantFase 1/2
- Dana-Farber Cancer Institute, Boston
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
ReclutantFase 1/2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Mosunetuzumab for CLL MRD Clearance
ReclutantFase 1/2
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
Reclutant
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital Cancer Center, Boston
HEME Home Transfusion Program
Reclutant
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Assaigs de Leucèmia en altres ciutats
- Houston, TX28 estudis
- New York City, NY19 estudis
- Los Angeles, CA16 estudis
- Chicago, IL16 estudis
- Durham, NC13 estudis
- Baldwin Park, CA12 estudis
- Columbus, OH12 estudis
- Nashville, TN12 estudis
- Philadelphia, PA12 estudis
- Milwaukee, WI11 estudis
- Atlanta, GA11 estudis
- Seattle, WA11 estudis
Altres estudis a Boston
- Càncer de mama111 estudis
- Càncer de pulmó de cèl·lules no petites90 estudis
- Càncer (tots els tipus)86 estudis
- Càncer colorrectal63 estudis
- Càncer metastàtic63 estudis
- Càncer de pulmó62 estudis
- Càncer d'ovari61 estudis
- Càncer de pròstata59 estudis
- Depressió52 estudis
- Càncer d'endometri50 estudis
- Insuficiència cardíaca44 estudis
- Leucèmia mieloide aguda44 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.